Showing results (71-80 of 141) with videos related to
Sort By:
Pageof 15
British Journal of Haematology|March 28, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.British Journal of Haematology|January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapseCyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.Blood|February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceBenjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA TrialAurore Perrot, Thierry Facon, Torben Plesner, et al.Blood|January 25, 2002
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialPhilippe Moreau, Thierry Facon, Michel Attal, et al.The New England Journal of Medicine|June 3, 2025
Measurable Residual Disease-Guided Therapy in Newly Diagnosed MyelomaAurore Perrot, Jérôme Lambert, Cyrille Hulin, et al.Bone Marrow Transplantation|May 25, 2020
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myelomaZoé Van de Wyngaert, Virginie Nerich, Guillemette Fouquet, et al.Lancet (London, England)|October 9, 2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialThierry Facon, Jean Yves Mary, Cyrille Hulin, et al.Pageof 15